February 28, 2022

Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation

Professor Palti is the inventor of Tumor Treating Fields, electric fields that disrupt cancer cell division The Israel Prize is regarded as the State of Israel’s highest cultural honor ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure’s Founder and Chief Technology Officer, has… Read More
learn more
February 24, 2022

Novocure’s General Counsel Resigns After 10 Years of Service

Todd Longsworth’s work was foundational to the growth of Novocure in becoming a global oncology company Barak Ben Arye has been appointed to General Counsel, effective April 1 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Todd Longsworth, General Counsel, has resigned. Mr. Longsworth’s last day… Read More
learn more
February 24, 2022

New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response

Tumor Treating Fields dually activates the STING and AIM2 pro-inflammatory signaling pathways that drive early anti-tumor immune responses ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption… Read More
learn more
February 24, 2022

Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Full year 2021 net revenues of $535 million, an increase of 8% year-over-year Invested record $201 million in 2021 in research and development initiatives intended to advance Tumor Treating Fields science and technology ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter… Read More
learn more